Southeastern Biosciences, An Under Appreciated Area
In the recent Price Waterhouse Coopers Money Tree Report for Q107, I was shocked to find that only four companies in the Southeast received seed/early stage funding from the reporting funding sources. Of the four, one received $20.5M, one $2.5M, one $50k and the other $28K. Several thoughts jumped out when I discovered this.
How many of us would consider $20.5M to be a seed stage investment. In a recent article, Tom Weithman, the Vice President of Entrepreneurship and Investment Services at the Center For Innovative Technology in Virginia, pointed out that the average seed/early stage ask from entrepreneurs is less than $400k, while the average seed/early stage investment is $2.5M. Clearly this is an indication of a market need that is being overlooked and under funded.
When I look around the Southeast, it is loaded with biosciences development and leadership talent. The wonderful university teaching centers such as UAB, EMORY, Vanderbilt, Medical College of Georgia, the University of Florida, the University of Tennessee, not to mention technology hubs like Huntsville, Nashville, Atlanta and Memphis, are producing great biosciences products and innovation. I am seeing many opportunities coming out of these institutions and markets and I am amazed there is not more funding being applied by Southeastern sources to grow Southeastern companies.
At Third Trimester, we are dedicated to this space. While the Northeast and Silicon Valley are the regions getting most of the biosciences funding, the Southeast remains an area of opportunity, growth and returns in the biosciences sector. I truly believe that over the next five years, the Southeast will challenge Boston and Silicon Valley and emerge as one of the premiere regions for innovative and valuable biosciences development. The common denominators for success are all here. There are many sources of available funding, there is a quality development environment that is supported by infrastructure and world class scientific talent, and there is a robust pool of experienced executive leadership who have run and managed bioscience companies. Innovation, deal flow and experienced leadership talent should equal success for the Southeast in biosciences.
